Mercy BioAnalytics
PrivateLast Round
Series B
Sep 3, 2025
Total Funding Raised
$127.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Mercy BioAnalytics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series B round in September 2025.
Mercy BioAnalytics is a biotechnology company that develops a liquid biopsy assay platform for the early detection of cancer through the analysis of tumor-derived extracellular vesicles.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mercy BioAnalytics Comparables
Compare Mercy BioAnalytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acuamark Diagnostics | 84% | |
| Mursla Bio | 82% | |
| Adela | 82% |
For institutional investors. Book with your work email.
Mercy BioAnalytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 3, 2025 | ||||
| Series A | Apr 3, 2023 | ||||
| Series A | Jan 29, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mercy BioAnalytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Research Horizons | Series A |
| Mindshift Capital | Series B |
| iSelect Fund | Series A, Series B |
| Perceptive Advisors | Series B |
| BrightEdge | Series A |
| Portfolia | Series B |
| Hatteras Venture Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 11, 2026
Launched Evident test portfolio for early cancer detection.
- Feb 4, 2026
Darrin Crisitello appointed as new Chief Commercial Officer.
For institutional investors. Book with your work email.
Mercy BioAnalytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mercy BioAnalytics's valuation, stock price, and market status.
Is Mercy BioAnalytics a public or private company?
Mercy BioAnalytics is a private company.
What is the current stock price of Mercy BioAnalytics?
Mercy BioAnalytics is a private company, so its shares have no public market price. Caplight tracks Mercy BioAnalytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mercy BioAnalytics worth (valuation)?
Valuation information for Mercy BioAnalytics is not publicly available.
Can I buy Mercy BioAnalytics stock?
Mercy BioAnalytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mercy BioAnalytics's last funding round?
Mercy BioAnalytics's most recent funding round was Series B on September 3, 2025.
Who are the main investors in Mercy BioAnalytics?
Key investors in Mercy BioAnalytics include Novalis LifeSciences, Sozo Ventures.
Will Mercy BioAnalytics IPO soon?
No public IPO plans have been announced for Mercy BioAnalytics.
How can I track Mercy BioAnalytics secondary market activity?
Caplight tracks bids, offers, and trades in Mercy BioAnalytics's shares on secondary markets.